Invention Grant
- Patent Title: Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof
-
Application No.: US16955975Application Date: 2018-12-21
-
Publication No.: US11242351B2Publication Date: 2022-02-08
- Inventor: Rima Al-awar , Methvin Isaac , Anh My Chau , Ahmed Mamai , Iain Watson , Gennady Poda , Pandiaraju Subramanian , Brian Wilson , David Uehling
- Applicant: Ontario Institute for Cancer Research (OICR)
- Applicant Address: CA Toronto
- Assignee: Ontario Institute for Cancer Research (OICR)
- Current Assignee: Ontario Institute for Cancer Research (OICR)
- Current Assignee Address: CA Toronto
- Agency: Bereskin & Parr LLP/S.E.N.C.R.L, s.r.l.
- Agent Patricia Folkins
- International Application: PCT/CA2018/051643 WO 20181221
- International Announcement: WO2019/119145 WO 20190627
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519 ; C07D487/14 ; A61P35/04 ; C07D471/14 ; C07D498/14 ; C07D519/00
Abstract:
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
Public/Granted literature
- US20210053978A1 TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF Public/Granted day:2021-02-25
Information query
